Independent stable KRAS-mutant and KRAS-wildtype CRC cells were generated that express shRNAs against Rab13 mRNA leading to a 70–80% reduction in Rab13 protein between the two distinct shRNA lines (Fig. 1A). This evidence concerns the gene RAB13 and colorectal carcinoma.